Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001214659-19-006702
Filing Date
2019-10-29
Accepted
2019-10-29 20:07:23
Documents
1
Period of Report
2019-10-25

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-45998.html 4  
1 PRIMARY DOCUMENT marketforms-45998.xml 4 3292
  Complete submission text file 0001214659-19-006702.txt   4819
Mailing Address 689 5TH AVENUE 12TH FLOOR NEW YORK NY 10022
Business Address
Kazam Joshua A (Reporting) CIK: 0001221355 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 191177015

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)